The potential use of PPARα agonists as immunosuppressive agents

Current Opinion in Investigational Drugs

Volumn 6, Issue 5, 2005, Pages 467-472

  Cunard, Robyn ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti inflammatory; Atherosclerosis; Fibrates; Peroxisome proliferator activated receptors

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BEZAFIBRATE; C REACTIVE PROTEIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GW 7647; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PERFLUOROOCTANOIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID; PLACEBO; PROSTACYCLIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; CLOFIBRIC ACID; IMMUNOSUPPRESSIVE AGENT;

ACUTE PHASE RESPONSE; AMYLOIDOSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ASTHENIA; ASTHMA; ATHEROSCLEROSIS; BILIARY CIRRHOSIS; BRAIN HEMORRHAGE; CANCER RISK; CLINICAL TRIAL; COLITIS; CONFORMATIONAL TRANSITION; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG CONFORMATION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMPOTENCE; INFLAMMATORY CELL; INSOMNIA; LIVER TOXICITY; MULTIPLE SCLEROSIS; MYOPATHY; NONHUMAN; PRECANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; TRANSCRIPTION REGULATION; ANIMAL; DRUG POTENTIATION; IMMUNOLOGY;

ANIMALS; CLOFIBRIC ACID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PPAR ALPHA;

EID: 18144378833     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (1990) 347(6294):645-650.
2. Evans RM: The steroid and thyroid hormone receptor superfamily. Science (1988) 240(4854):889-895.
3. Tsai MJ, O'Malley BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem (1994) 63:451-486.
4. Miyata KS, McCaw SE, Marcus SL, Rachubinski RA, Capone JP: The peroxisome proliferator-activated receptor interacts with the retinoid X receptor in vivo. Gene (1994) 148(2):327-330.
5. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology (1996) 137 (1):354-366.
6. Issemann I, Prince RA, Tugwood JD, Green S: The peroxisome proliferator-activated receptor: Retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol (1993) 11(1):37-47.
7. Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA (1997) 94 (9):4312-4317.
8. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA (1997) 94 (9):4318-4323.
9. 2 is a ligand for the adipocyte determination factor PPARγ. Cell (1995) 83(5):803-812.
10. Lehmann JM, Moore LB, Smith-Oliver TA, Willison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem (1995) 270(22):12953-12956.
11. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem (1997) 272(6):3406-3410.
12. Hatae T, Wada M, Yokoyama C, Shimonishi M, Tanabe T: Prostacyclin-dependent apoptosis mediated by PPARδ. J Biol Chem (2001) 276(49):46260-46267.
13. Glass CK, Rosenfeld MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev (2000) 14(2):121-141.
14. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S: The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J (1992) 11(2):433-439.
15. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature (1998) 391(6662):79-82.
16. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B: Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1. J Biol Chem (1999) 274(45):32048-32054.
17. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J: PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation (1999) 99(24):3125-3131.
18. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG: A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell (1996) 85(3):403-414.
19. Li M, Pascual G, Glass CK: Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol (2000) 20(13):4699-4707.
20. Delerive P, Gervois P, Fruchart JC, Staels B: Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators. J Biol Chem (2000) 275 (47):36703-36707.
21. Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD et al: Attenuation of colon inflammation through activators of the retinold X receptor (RXR)/peroxisome proliferator-activated receptor γ (PPARγ) heterodimer. A basis for new therapeutic strategies. J Exp Med (2001) 193(7):827-838.
22. Jones DC, Ding X, Zhang TY, Daynes RA: Peroxisome proliferator-activated receptor α negatively regulates T-bet transcription through suppression of p38 mitogen-activated protein kinase activation. J Immunol (2003) 171(1):196-203.
23. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B: Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem (1998) 273(40):25573-25580.
24. Woerly G, Honda K, Loyens M, Papin JP, Auwerx J, Staels B, Capron M, Dombrowicz D: Peroxisome proliferator-activated receptors α and γ down-regulate allergic inflammation and eosinophil activation. J Exp Med (2003) 198(3):411-421.
25. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J et al: Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature (1998) 393(6687):790-793.
26. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, Demer LL: Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol (1999) 19(9):2094-2104.
27. Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, Hedrick CC, Hama S, Borromeo C, Evans RM, Berliner JA, Nagy L: Role for peroxisome proliferator-activated receptor α in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res (2000) 87(6):516-521.
28. Cunard R, Ricote M, DiCampli D, Archer DC, Kahn DA, Glass CK, Kelly CJ: Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol (2002) 168(6):2795-2802.
29. Cunard R, DiCampli D, Archer DC, Stevenson JL, Ricote M, Glass CK, Kelly CJ: WY14,643, a PPARα ligand, has profound effects on immune responses in vivo. J Immunol (2002) 169(12):6806-6812.
30. Jones DC, Ding X, Daynes RA: Nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is expressed in resting murine lymphocytes. The PPARα in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem (2002) 277(9):6838-6845.
31. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W: The PPARα-leukotriene B4 pathway to inflammation control. Nature (1996) 384(6604):39-43.
32. Colville-Nash PR, Qureshi SS, Willis D, Willoughby DA: Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase 1. J Immunol (1998) 161(2):978-984.
33. Combs CK, Bates P, Karlo JC, Landreth GE: Regulation of β-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor α. Neurochem Int (2001) 39(5-6):449-457.
34. Spencer NF, Poynter ME, Im SY, Daynes RA: Constitutive activation of NF-κB in an animal model of aging. Int Immunol (1997) 9(10):1581-1588.
35. Poynter ME, Daynes RA: Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem (1998) 273(49):32833-32841.
36. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 136 (7):2348-2357.
37. Tam FW, Smith J, Karkar AM, Pusey CD, Rees AJ: Interleukin-4 ameliorates experimental glomerulonephritis and up-regulates glomerular gene expression of IL-1 decoy receptor. Kidney Int (1997) 52(5):1224-1231.
38. Tipping PG, Kitching AR, Huang XR, Mutch DA, Holdsworth SR: Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol (1997) 27(2):530-537.
39. Yang Q, Xie Y, Depierre JW: Effects of peroxisome proliferators on the thymus and spleen of mice. Clin Exp Immunol (2000) 122(2):219-226.
40. Yang Q, Xie Y, Eriksson AM, Nelson BD, DePierre JW: Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluoroctanoic acid in mice. Biochem Pharmacol (2001) 62(8):1133-1140.
41. Yang Q, Abedi-Valugerdi M, Xie Y, Zhao XY, Moller G, Nelson BD, DePierre JW: Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int Immunopharmacol (2002) 2(2-3):389-397.
42. Nelson DL, Frazier DE Jr, Ericson JE, Tarr MJ, Mathes LE: The effects of perfluorodecanoic acid (PFDA) on humoral, cellular, and innate immunity in Fischer 344 rats. Immunopharmacol Immunotoxicol (1992) 14(4):925-938.
43. Enioutina EY, Visic VD, Daynes RA: Enhancement of common mucosal immunity in aged mice following their supplementation with various antioxidants. Vaccine (2000) 18(22):2381-2393.
44. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD, Racke MK: Peroxisome proliferator-activated receptor α agonists as therapy for autoimmune disease. J Immunol (2004) 172(9):5790-5798.
45. Deplanque D, Gele P, Petrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R et al: Peroxisome proliferator-activated receptor-α activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci (2003) 23 (15):6264-6271.
46. Maruyama S, Kato K, Kodama M, Hirono S, Fuse K, Nakagawa O, Nakazawa M, Miida T, Yamamoto T, Watanabe K, Aizawa Y: Fenofibrate, a peroxisome proliferator-activated receptor α activator, suppresses experimental autoimmune myocarditis by stimulating the interleukin-10 pathway in rats. J Atheroscler Thromb (2002) 9(2):87-92.
47. Murai T, Yamada T, Miida T, Arai K, Endo N, Hanyu T: Fenofibrate inhibits reactive amyloidosis in mice. Arthritis Rheum (2002) 46(6):1683-1688.
48. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, Hosokawa M: Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res (2001) 61(6):2424-2428.
49. Trifilieff A, Bench A, Hanley M, Bayley D, Campbell E, Whittaker P: PPAR-α and -γ but not -δ agonists inhibit airway inflammation in a murine model of asthma: In vitro evidence for an NF-κB-independent effect. Br J Pharmacol (2003) 139(1):163-171.
50. Kanda T, Yokosuka O, Imazeki F, Saisho H: Bezafibrate treatment: A new medical approach for PBC patients? J Gastroenterol (2003) 38(6):573-578.
51. Okamoto H, Kamatani N: Successful treatment with fenofibrate, a peroxisome proliferator activated receptor α ligand, for a patient with rheumatoid arthritis. Ann Rheum Dis (2004) 63(8):1002-1003.
52. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med (1999) 340(2):115-126.
53. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med (1987) 317(20):1237-1245.
54. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet (1996) 347(9005):849-853.
55. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesaniemi YA, Pasternack A, Taskinen MR: Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation (1997) 96(7):2137-2143.
56. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Witt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med (1999) 341(6):410-418.
57. Duez H, Fruchart JC, Staels B: PPARs in inflammation, atherosclerosis and thrombosis. J Cardiovasc Risk (2001) 8(4):187-194.
58. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB et al: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial. J Am Med Assoc (2001) 285(12):1585-1591.
59. Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH: Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: Reversal with bezafibrate therapy in a randomized controlled trial. Am J Med (2002) 112(4):275-280.
60. Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, Kalina Z, Herman ZS: Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther (1998) 36(6):345-349.
61. Saitoh K, Mori T, Kasai H, Nagayama T, Ohbayashi S: Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. II: Anti-atheromatous effects are independent of its hypolipidemic effect in hereditary hyperlipidemic rabbits. Nippon Yakurigaku Zasshi (1995) 106(1):51-60.
62. Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, Fruchart JC et al: Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice. J Biol Chem (2002) 277(50):48051-48057.
63. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J Clin Invest (2004) 114(11):1564-1576.
64. Tillett WS, Francis T: Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med (1930) 52:561-571.
65. Black S, Kushner I, Samols D: C-reactive protein. J Biol Chem (2004) 279(47):48487-48490.
66. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 336(14):973-979.
67. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med (1994) 331(7):417-424.
68. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceske R, Hradec J: Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc Res (2001) 52(2):290-298.
69. Rizos E, Kostoula A, Elisaf M, Mikhailidis DP: Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology (2002) 53(3):273-277.
70. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T: Fibrates, down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFκB-C /EBP-β complex formation. Blood (2003) 101(2):545-551.
71. Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, Princen HM, Kooistra T: Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood (2004) 103(11):4188-4194.
72. Yamazaki K, Kuromitsu J, Tanaka I: Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator-activated receptor α agonists. Biochem Biophys Res Commun (2002) 290(3):1114-1122.
73. Mouthiers A, Baillet A, Delomenie C, Porquet D, Mejdoubi-Charef N: PPARα physically interacts with C/EBPβ to inhibit C/EBPβ-responsive α1-acid glycoprotein gene expression. Mol Endocrinol (2005):doi:10.1210/me.2004-0188.
74. Gervois P, Vu-Dac N, Kleemann R, Kockx M, Dubois G, Laine B, Kosykh V, Fruchart JC, Kooistra T, Staels B: Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT box/enhancer-binding protein β. J Biol Chem (2001) 276(36):33471-33477.
75. Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, Kooistra T: Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-α activator fenofibrate. J Biol Chem (2004) 279(16):16154-16160.
76. Roberts RA, James NH, Hasmall SC, Holden PR, Lambe K, Macdonald N, West D, Woodyatt NJ, Whitcome D: Apoptosis and proliferation in nongenotoxic carcinogenesis: Species differences and role of PPARα. Toxicol Lett (2000) 112-113:49-57.
77. Chevalier S, Roberts RA: Perturbation of rodent hepatocyte growth control by nongenotoxic hepatocarcinogens: Mechanisms and lack of relevance for human health (review). Oncol Rep (1998) 5(6):1319-1327.
78. Law MR, Thompson SG, Wald NJ: Assessing possible hazards of reducing serum cholesterol. Br Med J (1994) 308(6925):373-379.
79. Tomlinson B, Chan P, Lan W: How well tolerated are lipid-lowering drugs? Drugs Aging (2001) 18(9):665-683.
80. Newman TB, Hulley SB: Carcinogenicity of lipid-lowering drugs. J Am Med Assoc (1996) 275(1):55-60.
81. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation (2000) 102(1):21-27,
82. Blane GF: Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med (1987) 83(5B):26-36.
83. Rabasa-Lhoret R, Rasamisoa M, Avignon A, Monnier L: Rare side-effects of fenofibrate. Diabetes Metab (2001) 27(1):66-68.
84. Shepherd J: Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety. Eur Heart J (1995) 16(1):5-13.
85. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ: Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol (1995) 15(6):3012-3022.
86. Brown PJ, Stuart LW, Hurley KP, Lewis MC, Winegar DA, Wilson JG, Wilkison WO, Ittoop OR, Willson TM: Identification of a subtype selective human PPARα agonist through parallel-array synthesis. Bioorg Med Chem Lett (2001) 11(9):1225-1227.
87. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM: PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med (2001) 7(1):48-52.
88. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature (2000) 403(6765):103-108.
89. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci USA (2000) 97(9):4844-4849.
90. 2 in activated murine macrophages. Mol Cell Biol (2000) 20 (5):1692-1698.
91. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res (2001) 61(16):6213-6218.